1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > CNS Drug News 03 NOVEMBER 2014

CNS Drug News 03 NOVEMBER 2014

  • November 2014
  • -
  • Espicom Business Intelligence
  • -
  • 24 pages

Industry Trend Analysis - Preventive Migraine Treatment: A Significant Commercial Opportunity
Industry Brief - Genervon Reports GM6 Phase IIa Trial Results In ALS/PD
Industry Brief - Additional ADS-5102 Phase III Trial Initiated In PD Patients With LID
Industry Brief - Astellas/CoMentis To End Alzheimer's Collaboration
Industry Brief - TWi Receives FDA Donepezil Approval
Industry Brief - Results From Two Phase III Studies Added To Aubagio's US Label
Industry Brief - Laquinimod Clinical Development Programme Expanded
Industry Brief - First Patient Enrolled In Vatelizumab Phase II RRMS Trial
Industry Brief - FDA Responds To Antisense's IND Application For ATL1102 Phase IIb MS Trial
Industry Brief - Breckenridge/Natco Gain US Armodafinil Tentative Approval
Industry Brief - Mundipharma Receives Positive CHMP Opinion For Targin In RLS
Industry Brief - GSK/SDP To Terminate Paxil CR Co-Promotion In Japan
Industry Brief - Health Canada Approves Trintellix For Adults With MDD
Industry Brief - ex scientia/Sunovion Partner To Research New Medicines For Psychiatric Disorders
Industry Trend Analysis - Aripiprazole Lauroxil Has Potential To Fuel Future Growth For Alkermes
Industry Brief - Alexza/Ferrer Expand Partnership For Adasuve
Industry Brief - Actavis Initiates Methylphenidate Patent Challenge
Industry Trend Analysis - Pfizer's Embeda Taps Into Growing Need For Abuse-Deterrent Opioids
Industry Brief - Zogenix/Purdue Exchange Waivers Of Regulatory Exclusivity For ER Hydrocodone Products
Industry Brief - Pivotal Phase III Results Published From AVP-825 Acute Migraine Study
Industry Brief - Acura Provides Update On Hydrocodone With Acetaminophen Tablet Development
Industry Brief - Orexo Submits Application To FDA For Expanded Zubsolv Label
Industry Brief - Bunavail Commercially Available In US
Industry Trend Analysis - BDSI Targets Further Opioid-Dependence Market Penetration With Long-Lasting Injectable
Industry Brief - FDA Grants Eisai's sNDA For Banzel Priority Review
Industry Brief - FDA Accepts Fycompa sNDA As Adjunctive Treatment Of PGTC Seizures
Industry Brief - GW's Epidiolex Receives Orphan Designation From EMA For Dravet Syndrome
Industry Brief - Positive Zonegran Results In Pivotal Extension Study
Industry Brief - Lundbeck Receives Carbella CRL From FDA
Industry Brief - Vimpat Phase III Study Meets Primary Endpoint In Japanese/Chinese POS Patients
Industry Brief - GW Begins Phase II/III Trial Of Epidiolex In Dravet Syndrome
Industry Brief - Contrave Available In US Pharmacies
Industry Brief - Neurocrine Initiates Phase III Study Of VMAT2 Inhibitor In TD
Industry Brief - SAGE-547 Phase IIa Trial Initiated In Essential Tremor
Industry Brief - FDA Grants ODD To Ultragenyx' Triheptanoin
Industry Brief - Neurocrine Receives Breakthrough Therapy Designation For NBI-98854 In TD
Industry Brief - Auspex Initiates Second Phase III Trial For SD-809 In TD
Industry Trend Analysis - Shire/AbbVie Combination Now Unlikely
Industry Brief - AbbVie/Shire Agree To Terminate Proposed Merger
Industry Brief - Therapix Signs Non-Binding Agreement To Acquire Dekel Pharmaceuticals
Industry Brief - Forward Pharma Prices IPO
Industry Brief - Relmada Adds USD15mn In Capital To Expedite Development Of Pain Drugs
Industry Brief - Zogenix Acquires UK-Based Brabant Pharma

Table Of Contents

CNS Drug News 03 NOVEMBER 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Alcoholism and drug dependence and addiction, known as substance use disorders and rehabilitation treatments are classified as substance abuse treatment. Some of the common symptoms of drug abuse are ...

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Psychotherapeutic drugs are used to treat mental illnesses such as extreme mood swings, social withdrawal, long lasting depression, confused thinking, and suicidal thought. schizophrenia, bipolar disorder, ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.